We serve Chemical Name:6-acetyltetrahydronaphthalene CAS:774-55-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-acetyltetrahydronaphthalene
CAS.NO:774-55-0
Synonyms:1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanone;EINECS 212-266-7;MFCD00019710
Molecular Formula:C12H14O
Molecular Weight:174.23900
HS Code:2914399090
Physical and Chemical Properties:
Melting point:-21°C
Boiling point:119-121°C 2mm
Density:1,058 g/cm3
Index of Refraction:1.5610
PSA:17.07000
Exact Mass:174.10400
LogP:2.76800
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3082 9/PG 3
Packing Group:
Contact us for information like 1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00019710 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanone Use and application,EINECS 212-266-7 technical grade,usp/ep/jp grade.
Related News: China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. 6-acetyltetrahydronaphthalene manufacturer Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 6-acetyltetrahydronaphthalene supplier China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. 6-acetyltetrahydronaphthalene vendor Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 6-acetyltetrahydronaphthalene factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?
